$0.68 EPS Expected for Sanofi (SNY); Indus Capital Partners Has Boosted New Oriental Ed & Tech Grp I (EDU) Position By $23.75 Million

January 14, 2018 - By Nellie Frank

Analysts expect Sanofi (NYSE:SNY) to report $0.68 EPS on February, 14.They anticipate $0.01 EPS change or 1.49% from last quarter’s $0.67 EPS. SNY’s profit would be $1.70 billion giving it 16.46 P/E if the $0.68 EPS is correct. After having $1.00 EPS previously, Sanofi’s analysts see -32.00% EPS growth. The stock increased 1.75% or $0.77 during the last trading session, reaching $44.78. About 1.66M shares traded or 34.41% up from the average. Sanofi (NYSE:SNY) has risen 26.96% since January 14, 2017 and is uptrending. It has outperformed by 10.26% the S&P500.

Indus Capital Partners Llc increased New Oriental Ed & Tech Grp I (EDU) stake by 192.79% reported in 2017Q3 SEC filing. Indus Capital Partners Llc acquired 269,900 shares as New Oriental Ed & Tech Grp I (EDU)’s stock rose 45.08%. The Indus Capital Partners Llc holds 409,900 shares with $36.18M value, up from 140,000 last quarter. New Oriental Ed & Tech Grp I now has $16.59 billion valuation. The stock increased 2.94% or $3 during the last trading session, reaching $104.92. About 2.50 million shares traded or 58.59% up from the average. New Oriental Education & Technology Group Inc. (NYSE:EDU) has risen 76.69% since January 14, 2017 and is uptrending. It has outperformed by 59.99% the S&P500.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $112.08 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 10.42 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Among 12 analysts covering Sanofi-aventis Sa (NYSE:SNY), 1 have Buy rating, 1 Sell and 10 Hold. Therefore 8% are positive. Sanofi-aventis Sa had 23 analyst reports since October 15, 2015 according to SRatingsIntel. The rating was downgraded by Morgan Stanley to “Underweight” on Friday, December 1. The firm has “Hold” rating by HSBC given on Wednesday, August 30. The stock of Sanofi (NYSE:SNY) earned “Hold” rating by Berenberg on Thursday, May 11. The stock of Sanofi (NYSE:SNY) earned “Sell” rating by JP Morgan on Friday, March 31. HSBC downgraded Sanofi (NYSE:SNY) on Tuesday, May 3 to “Hold” rating. Cowen & Co maintained Sanofi (NYSE:SNY) on Friday, October 13 with “Hold” rating. HSBC downgraded the shares of SNY in report on Friday, April 7 to “Reduce” rating. Bernstein downgraded Sanofi (NYSE:SNY) on Monday, November 9 to “Mkt Perform” rating. The stock of Sanofi (NYSE:SNY) has “Buy” rating given on Thursday, April 6 by Argus Research. On Tuesday, September 5 the stock rating was maintained by Cowen & Co with “Hold”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>